Smart + Strong.
All Rights Reserved.
Smart + Strong®
is a registered trademark of CDM Publishing, LLC.
However, the regimen appears much less potent for those who aren’t virally suppressed.
Researchers have presented 96-week results from an advanced trial of Symtuza compared with Prezcobix plus Truvada.
Among those taking Epivir, taking two antiretrovirals instead of three was tied to fewer people stopping because of side effects.
Researchers compared switching to Symtuza with staying on an effective regimen of a boosted protease inhibitor plus Truvada.
Compared with a regimen based on Prezista, doravirine was better for blood lipids, including cholesterol and triglycerides.
The single-tablet antiretroviral regimen includes Janssen’s darunavir plus Gilead’s cobicistat, emtricitabine and tenofovir alafenamide.
Delstrigo (doravirine/lamivudine/tenofovir disoproxil fumarate) includes Pifeltro (doravirine) in a three-drug single-tablet regimen.
A speedy overview of the major scientific findings presented at the International AIDS Conference in Amsterdam (AIDS 2018)
A South African study found that this cost-savings measure did not change the likelihood of viral suppression after 48 weeks.
Janssen’s single-tablet antiretroviral regimen was approved on July 17.
This connection remained even when researchers took into account various risk factors for cardiovascular disease.
Most of such drug resistance seen is to older drugs.
A recent analysis of Europeans taking boosted protease inhibitors for HIV treatment found this pair prompted the best long-term response.
The new drug application is for doravirine as both an individual tablet and part of a combination tablet.
You have been inactive for 60 minutes and will be logged out in . Any updates not saved will be lost.
Click here to log back in.